Eisai EMEA Revenue and Competitors
Estimated Revenue & Valuation
- Eisai EMEA's estimated annual revenue is currently $228.9M per year.
- Eisai EMEA's estimated revenue per employee is $201,000
Employee Data
- Eisai EMEA has 1139 Employees.
- Eisai EMEA grew their employee count by 7% last year.
Eisai EMEA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $58.9M | 293 | 6% | N/A | N/A |
#2 | $21.1M | 105 | 5% | N/A | N/A |
#3 | $113.4M | 564 | 1% | N/A | N/A |
#4 | $20.9M | 104 | -5% | N/A | N/A |
#5 | $37M | 184 | 9% | N/A | N/A |
#6 | $45.4M | 226 | -24% | N/A | N/A |
#7 | $16.1M | N/A | N/A | N/A | |
#8 | $69.7M | 347 | 0% | N/A | N/A |
#9 | $8M | 40 | 3% | N/A | N/A |
#10 | $25.5M | 127 | 28% | N/A | N/A |
What Is Eisai EMEA?
Welcome to the Eisai EMEA. Eisai (pronounced 'Ä?-zÄ«â??) is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world. \n\nEisai is one of the world's leading research-based pharmaceutical companies. We define our corporate mission as "giving first thought to patients and their families, and to increasing the benefits health care provides," which we call human health care (hhc). With operations in the U.S., Asia, Europe, Russia, India, Africa, the Middle East, Australia and it's domestic home market of Japan, Eisai employs more than 11,000 people worldwide.\n\nOur main focuses are within Oncology & Neurology (dementia-related diseases and neurodegenerative diseases).
keywords:N/A
N/A
Total Funding
1139
Number of Employees
$228.9M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eisai EMEA News
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with ... which have held up approvals in Europe and Japan.
Other Companies in Hatfield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $352.7M | 1145 | 6% | N/A |
#2 | $473.6M | 1253 | 8% | N/A |
#3 | $752.2M | 1990 | 14% | N/A |
#4 | $660.4M | 2078 | 11% | N/A |
#5 | $582.6M | 2870 | 6% | N/A |